NICE announcement, 201 September 2017: Surveillance report 2017 – Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management (2007) NICE guideline CG53
We will plan a full update with a modified scope of the guideline on chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) (NICE guideline CG53).
Reason for the decision
Assessing the evidence
Initial assessment of the evidence against the guideline scope indicated that there was no clear signal that the identified new evidence would result in changes to the recommendations (see appendix A: pre-consultation summary of evidence from surveillance). Following a stakeholder consultation on the proposal to not update the guideline, broader issues with the guideline were highlighted that called into question the guideline scope and its current relevance.
After further consideration of information from stakeholders including new evidence (see appendix B: summary of evidence highlighted to NICE during consultation, and appendix C: stakeholder consultation comments table) alongside the evidence identified through the surveillance review, NICE has decided to fully update the guideline with a modified scope.
No equalities issues were identified during the surveillance process.
After considering all the evidence and views of topic experts, we decided that a full update with modified scope is necessary for this guideline.
See how we made the decision for further information.